The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

TREATMENT OF SEVERE DEPRESSION WITH DESIPRAMINE, A METABOLITE OF IMIPRAMINE

Published Online:https://doi.org/10.1176/ajp.120.5.494

Desipramine, an active metabolite of imipramine, was administered to 129 patients with severe depressive disorders. The majority had a history of 1 to 4 depressive attacks. In most cases, the drug was given for 2 to 4 months in daily doses of 75 or 100 mg. (i.m.) for a few days, followed by 100 to 150 mg. orally, thereafter. Tranquilizers were given concurrently as required to control agitation, anxiety or insomnia.

Desipramine produced a satisfactory clinical response in 99 (76.4%) patients. Compared to imipramine, used in previous studies, the new drug seems to be slightly more potent on a dose-size basis; it has a faster onset of action, evident in 2 to 7 days, and side effects appear to be milder and of shorter duration.

Because of its rapid onset of action and mild side effects, desipramine may prove particularly useful in reducing the need for prolonged hospitalization in severe depressive conditions.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.